Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
AARD Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 02, 2026
Report Source: 2026 1st Quarter Report
Aardvark Therapeutics Inc. Stock Analysis AARD
United States Health Care Micro Cap Report: Aardvark Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in San Diego, California and currently employs 40 full-time employees. The company went IPO on 2025-02-13. The firm targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. The company is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
Read More Aardvark Therapeutics Inc (AARD) Chart
Key Statistics of Aardvark Therapeutics Inc (AARD)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$4.06Volume
112.40KP/E Ratio (TTM)
-52 Week Range
Market Cap
98.39MAvg. Volume
134.16KDividend Yield
-Financial Metrics & Statements of Aardvark Therapeutics Inc (AARD)
FAQ's for Aardvark Therapeutics Inc (AARD)
- According to Musaffa’s Shariah screening methodology, Aardvark Therapeutics Inc (AARD) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Aardvark Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Aardvark Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Aardvark Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Aardvark Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Aardvark Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.